Trial: 202202093

A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors


I/II (Cancer Control)

Principal Investigator

Van Tine, Brian

Disease Site

Bones and Joints; Soft Tissue

Learn more about this study at: